Chemical Information | |
Antiviral agent ID | DrugRepV_1358 | |
Antiviral agent name | Levocarnitine | |
IUPAC Name | (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate | |
SMILES (canonical) | C[N+](C)(C)CC(CC(=O)[O-])O | |
SMILES (isomeric) | C[N+](C)(C)C[C@@H](CC(=O)[O-])O | |
Molecular Formula | C7H15NO3 | |
Molecular Weight (g/mol) | 161.201 | |
InChl | InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1 | |
Common Name | L-Carnitine | |
Synonyms | (-)-Carnitine | (-)-L-Carnitine | (R)-Carnitine | 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt | Carnitine | Levocarnitin | Levocarnitina | LĂ©vocarnitine | Levocarnitine | Levocarnitinum | Vitamin BT | |
Structural Information | |
|
|
Clinical Information | |
Category | Alimentary Tract and Metabolism
| |
Primary Indication (Clinical trial phases) | Approved, Investigational
| |
Biological Information | |
Primary Indication (Disease Category) | Non Infectious Disease
| |
Primary Indication (Disease) | Carnitine deficiency | Hyperlipoproteinemias
| |
Primary Indication (Drug target/Mode of Action) | Butyrophilin-like protein 3
| |
Secondary Indication | Zika virus (ZIKV) NA MEX_I_7 | |
Secondary Indication (Approaches) | Experimental-HTS | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Huh-7
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 0.4 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Pre infection (1 hour)
| |
Secondary Indication (Duration of drug delivery) | 24-26 hours
| |
Secondary Indication (Drug concentration) | 13.8 μM
| |
Secondary Indication (Cell based assay) | Fluorescence-based assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | Percentage Inhibition [ 45.09 % ] | |
Reference | Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Muñoz.A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection..Cell Host Microbe. 2016 Aug 10;20(2):259-70. doi: 10.1016/j.chom.2016.07.004. Epub 2016 Jul 28. PMID:27476412
| |
Comment | Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.
| |